AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy ...Middle East

Current investors in AMO Pharma increase funding as Company passes two-thirds enrollment milestone in REACH-CDM pivotal clinical trial LONDON, May 10, 2022 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset...

Hence then, the article about amo pharma announces additional private equity investment following progress in phase 3 study in congenital myotonic dystrophy was published today ( Tuesday 10/05/2022 - 11:22 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy )

Also on site :

• The Official Happiest Country in the World Has Charming Seaside Towns, Castles, and Unique Experiences
• ‘Big Little Lies’ Author Teases Sequel Book, ‘Big Little Truths,’ And Season 3 Plot: “A Time Jump Always Made Sense To Me”
• Super Micro Computer Issues Statement on Action by U.S. Attorney's Office